Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

AbbVie acquires Allergan: unpicking the year-long approval process

AbbVie’s $63bn acquisition of Allergan has been in the works since June 2019. It aims to diversify AbbVie’s portfolio beyond its blockbuster product Humira and create cost efficiencies in R&D and commercialisation activities. What slowed down its approval, particularly by US regulatory authorities?

Close
Close
Close

Go Top